Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Tananbaum James B. 2. Issuer Name and Ticker or Trading Symbol Latigo Biotherapeutics, Inc. [LTGO] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O LATIGO BIOTHERAPEUTICS, INC., 1300 RANCHO CONEJO BLVD., SUITE 305 3. Date of Earliest Transaction (Month/Day/Year) 08/10/2026 (Street) THOUSAND OAKS, CA 91320 4. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 08/10/2026 C 3,117,664 A (1) 3,117,664 I See footnote(2) Common Stock 08/10/2026 C 445,320 A (1) 3,562,984 I See footnote(2) Common Stock 08/10/2026 C 1,125,823 A (1) 1,125,823 I See footnote(3) Common Stock 08/10/2026 C 742,201 A (1) 1,868,024 I See footnote(3) Common Stock 08/10/2026 P 140,000 A $18 2,008,024 I See footnote(3) Common Stock 08/10/2026 C 195,776 A (4) 2,203,800 I See footnote(3) Common Stock 08/10/2026 C 3,117,664 A (1) 3,117,664 I See footnote(5) Common Stock 08/10/2026 C 296,880 A (1) 3,414,544 I See footnote(5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A-2 Convertible Stock	(1)	08/10/2026		C			3,117,664	(1)	(1)	Common Stock	3,117,664	(1)	0	I	See footnote(2)
Series B Convertible Preferred Stock	(1)	08/10/2026		C			445,320	(1)	(1)	Common Stock	445,320	(1)	0	I	See footnote(2)
Series A-2 Convertible Preferred Stock	(1)	08/10/2026		C			1,125,823	(1)	(1)	Common Stock	1,125,823	(1)	0	I	See footnote(3)
Series B Convertible Preferred Stock	(1)	08/10/2026		C			742,201	(1)	(1)	Common Stock	742,201	(1)	0	I	See footnote(3)
Series A-2 Convertible Preferred Stock	(1)	08/10/2026		C			3,117,664	(1)	(1)	Common Stock	3,117,664	(1)	0	I	See footnote(5)
Series B Convertible Preferred Stock	(1)	08/10/2026		C			296,880	(1)	(1)	Common Stock	296,880	(1)	0	I	See footnote(5)
Convertible Promissory Note	(4)	08/10/2026		C			195,776	(4)	(4)	Common Stock	195,776	(4)	0	I	See footnote(3)

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Tananbaum James B. C/O LATIGO BIOTHERAPEUTICS, INC. 1300 RANCHO CONEJO BLVD., SUITE 305 THOUSAND OAKS, CA 91320	X	X

Signatures

/s/ Sabrina Nieder, Attorney-in-Fact		08/10/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Each share of preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date.
(2)	The securities are held of record by Foresite Capital Fund V, L.P. (Fund V). Foresite Capital Management V, LLC (FCM V) is the general partner of Fund V and may be deemed to have sole voting and dispositive power over the securities held by Fund V. The Reporting Person is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over the securities held by Fund V. Each of Fund V, FCM V and the Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
(3)	The securities are held of record by Foresite Capital Fund VI, LP (Fund VI). Foresite Capital Management VI, LLC (FCM VI) is the general partner of Fund VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. The Reporting Person is the sole managing member of FCM VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. Each of Fund VI, FCM VI and the Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
(4)	Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock.
(5)	The securities are held of record by Foresite Capital Opportunity Fund V, L.P. (Opportunity Fund V). Foresite Capital Opportunity Management V, LLC (FCOM V) is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over the shares held by Opportunity Fund V. The Reporting Person is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over the securities held by Opportunity Fund V. Each of Opportunity Fund V, FCOM V and the Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.